A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)

Next Previous
Trial Profile

A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs Elotuzumab (Primary) ; Bortezomib; Bortezomib; Dexamethasone; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma; Plasma cell leukaemia
  • Focus Therapeutic Use
  • Acronyms SWOG 1211

    • Most Recent Events

    • 31 Mar 2016 Time frame for primary endpoint changed from 2 years to upto 6 years as reported by ClinicalTrials.gov record.
    • 31 Mar 2016 Planned primary completion date changed from 1 Nov 2018 to 1 Sep 2018 as reported by ClinicalTrials.gov record.
    • 02 Jun 2014 The study design presented at 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top